Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.
|Articles|February 11, 2010
Diabetes related topics
On This Page • Diabetes Q&A • Images in Diabetes • Juvenile Diabetes • Diabetes and Mental Health • Guidelines and Recommendations • News • Patient Resources • Tools
Advertisement
On This Page
•
•
•
•
•
•
•
•
Advertisement
Related to this article
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
Advertisement
Advertisement
Trending on Patient Care Online
1
Updated Freenome CRC Blood Test Detects 18.2% of Advanced Precancerous Lesions
2
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
3
Real-World Nonhormonal Therapy Effects on VMS Bother, Work, and Mood
4
Why Real-World Evidence Matters for Nonhormonal Menopause VMS Therapy
5